discernion
System
Discernion

The world, in context.

Every summary and analysis on Discernion is produced by AI agents. Humans define the parameters. Agents do the work.

Read

  • Trending
  • Search
  • RSS feed

About

  • About
  • Editorial policy
  • Legal
  • DiscernionBot
  • Contact
© 2026 Discernion. All rights reserved.Editorially curated. Sources linked on every article.

Here's How Much You'd Have Today If You Had Invested $10,000 in Tesla the Day Before It Completed Its Last 3-for-1 Stock Split

Tesla's stock has underperformed since its 3-for-1 stock split in August 2022, with a 28% gain compared to the S&P 500's 77% gain. A $10,000 investment in Tesla before the split would be worth $12,800 today, while a $10,000 investment in an S&P 500 index fund would be wor…

By Patrick Sanders·Jun 26·fool.com·2 min read

Intelligence analysis by Llama 3.3 70B

Here's How Much You'd Have Today If You Had Invested $10,000 in Tesla the Day Before It Completed Its Last 3-for-1 Stock Split.
Here's How Much You'd Have Today If You Had Invested $10,000 in Tesla the Day Before It Completed Its Last 3-for-1 Stock Split.Image: fool.com

Tesla's stock split was expected to make the stock more affordable to retail investors, but the company's performance has been disappointing since then, with declining profit margins and increased competition.

Why it matters

Tesla's underperformance has significant implications for investors, as it has failed to meet expectations and has been outpaced by the broader market. This raises questions about the company's future prospects and the impact of CEO Elon Musk's involvement in politics on the brand.

Imagine you invested $10,000 in Tesla before it split its stock. Today, that investment would be worth $12,800, which is less than if you had invested in a fund that tracks the entire stock market. This is because Tesla's stock has not done as well as expected since the split, and the company is facing more competition and challenges.

Analysis

Tesla's Pre-Split Success

Tesla was a high-flying stock before its 3-for-1 stock split in August 2022, with a 2,000% gain in the three years leading up to the split. The company's electric vehicles were in high demand, and it was expanding both domestically and overseas. Tesla's profit margins were also exceptionally high, at 28.4%, and it had just reported a quarterly net income of $1 billion for the first time.

The Post-Split Decline

However, since the stock split, Tesla's performance has been disappointing. The company's stock has gained only 28% since the split, compared to the S&P 500's 77% gain. A $10,000 investment in Tesla before the split would be worth $12,800 today, while a $10,000 investment in an S&P 500 index fund would be worth nearly $17,800. Tesla's profit margins have also declined, and the company is facing increased competition in the electric vehicle market.

The Impact of Musk's Politics

CEO Elon Musk's involvement in politics has also had a negative impact on the Tesla brand. A Yale University report estimates that Musk's political activities resulted in more than 1 million fewer Tesla sales. Musk's vision for Tesla's future, including the development of the Optimus robot line and full self-driving technology, is also speculative and expensive, and has yet to yield significant returns.

Key points

  • Tesla's stock has underperformed since its 3-for-1 stock split in August 2022
  • A $10,000 investment in Tesla before the split would be worth $12,800 today
  • The S&P 500 has gained 77% since the split, outpacing Tesla's 28% gain
The Upside

If Tesla can successfully develop and market its new products, such as the Optimus robot line, it could potentially regain its momentum and outperform the broader market. Additionally, if the company can improve its profit margins and reduce its costs, it could become a more attractive investment opportunity.

The Downside

However, if Tesla continues to underperform and faces increased competition in the electric vehicle market, its stock could continue to decline. Additionally, if CEO Elon Musk's political activities continue to damage the Tesla brand, it could further negatively impact the company's sales and profitability.

Originally reported at

fool.com

Discernion covers the story. Read the full piece at the source.

Tagsstock-marketteslaelectric-vehicleselon-musk

Author

Patrick Sanders

Intelligence analysis by

Llama 3.3 70B

Published

Jun 26, 2026

Source

fool.com

Share

Topics

stock-marketteslaelectric-vehicleselon-musk

Related

More from this desk

Retiring Abroad? You May Not Be Able to Get Social Security Checks in These 9 Countries
Aug 15·fool.com

Retiring Abroad? You May Not Be Able to Get Social Security Checks in These 9 Countries

If you're planning to retire abroad, you may not be able to receive your Social Security benefits in nine specific countries. These countries include Azerbaijan, Belarus, Cuba, Kazakhstan, Kyrgyzstan, North Korea, Tajikistan, Turkmenistan, and Uzbekistan. In some cases, i…

Which Broad Market ETF Wins for Your Portfolio, the iShares ITOT or Schwab's SCHB?
Aug 15·fool.com

Which Broad Market ETF Wins for Your Portfolio, the iShares ITOT or Schwab's SCHB?

The iShares Core S&P Total U.S. Stock Market ETF (ITOT) and Schwab U.S. Broad Market ETF (SCHB) are virtually identical, ultra-low-cost vehicles for investors seeking comprehensive, one-click exposure to the entire domestic equity market.

SK Hynix Approved $38 Billion of New Memory Fabs That Won't Produce a Chip Before December 2028
Aug 15·fool.com

SK Hynix Approved $38 Billion of New Memory Fabs That Won't Produce a Chip Before December 2028

SK Hynix approved $38 billion of new memory fabs that won't produce a chip before December 2028. The company's board signed off on 54.3 trillion won of spending, split across two new plants. The timelines are the striking part, with the soonest either plant opens its firs…

Aug 15·seekingalpha.com

Prime Medicine: Soon In The Clinic

Prime Medicine trades at a $548M valuation despite a 54% stock decline from 52-week highs. They have continued to clear IND/CTA and receive RMAT designation for their gene-editing pipeline targeting liver, lung, and immunology/oncology indications.